Radiother Oncol: cytoximatoxamcine-RT combined avic monotorthescans can be used to treat patients with advanced HNSCC who are not suitable for cisplatin treatment.

Cytoxisionmonotherapy (RT) is an option for patients with advanced head and neck squamous cell carcinoma (HNSCC) who are not suitable for cisplatin treatment.
testing PD-L1 immunocheckpoint blocking (avelumab) and sitoxiumitis-RT in therapeutic settings is meaningful because the total survival rate for 5 years is less than 50%.
phase-I feasibility test for patients with advanced HNSCC who are not suitable for cisplatin treatment (simultaneously maintained at 10mg/kg Q2W plus 4 months) phase-I feasibility test (plan n, NCT02938273).
results, 1 out of 10 patients included had a level 2 sitoximax-related infusion reaction and exited the study before avic monotonica.
1 patient ended treatment after 2 courses of aviitonitation and 12 x 2Gy RT for personal reasons.
the remaining 2/8 patients stopped avic monobify treatment after 4 courses and 8 courses of course due to toxicity and tumor progression, respectively.
no 4-5 toxicity.
level 3 immunotoxicity is controllable and occurs in 4 patients.
1 patient received topical steroid treatment for a level 3 large herpes rash, and 3 patients received a large dose of pernison treatment due to an elevated level 3 hepatoenzyme (n s 1) and pneumonia (n s 2).
7 patients had level 3 RT-related toxicity withno serious specific sytoxib-related toxicity.
a median follow-up 12 (8-26) months later, 4/8 patients (50%) had a recurrence of the tumor.
in general, sitoxioxion-RT Gaaveit is feasible for patients with advanced HNSCC who are not suitable for cisplatin treatment.
immunotoxicity is short-lived and controllable, and radiotherapy-related toxicity meets standard treatment.
the pilot study provides the basis for larger efficacy trials.
.